Microneedles for Proteins and Peptides Delivery: Current Aspect and Future Perspective
Main Article Content
Abstract
More than half of the top 20 most famous drugs fall under biopharmaceuticals, with projections indicating a $388
billion value by 2024 that shows how effective protein, peptide, and antibody-based treatments are. However, the
methods for effective medication delivery have been limited by the inherent characteristics of biopharmaceuticals.
Although the intravenous route offers 100% bioavailability, patients frequently link it with discomfort and needle
anxiety, which might result in resistance to receiving necessary therapy. Since then, several non-invasive techniques
have been developed to get beyond these restrictions. One such tactic is microneedles (MNs), which can painlessly
pierce the stratum corneum barrier and significantly improve transdermal medication delivery of various medicines.
This review summarizes several studies that strive to enhance MN-based transdermal biopharmaceutical delivery.
The ability to increase MN production at a lower cost and the application’s long-term safety will be key factors
in determining the full potential of MNs as a drug delivery technology for biopharmaceuticals. Thus, the existing
obstacles to the clinical translation of MNs are also examined, along with potential solutions.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.